1. Home
  2. EMR vs SONN Comparison

EMR vs SONN Comparison

Compare EMR & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EMR
  • SONN
  • Stock Information
  • Founded
  • EMR 1890
  • SONN N/A
  • Country
  • EMR United States
  • SONN United States
  • Employees
  • EMR N/A
  • SONN N/A
  • Industry
  • EMR Consumer Electronics/Appliances
  • SONN Biotechnology: Pharmaceutical Preparations
  • Sector
  • EMR Technology
  • SONN Health Care
  • Exchange
  • EMR Nasdaq
  • SONN Nasdaq
  • Market Cap
  • EMR N/A
  • SONN 4.6M
  • IPO Year
  • EMR N/A
  • SONN N/A
  • Fundamental
  • Price
  • EMR $112.55
  • SONN $1.28
  • Analyst Decision
  • EMR Buy
  • SONN Strong Buy
  • Analyst Count
  • EMR 15
  • SONN 2
  • Target Price
  • EMR $128.20
  • SONN $38.00
  • AVG Volume (30 Days)
  • EMR 3.0M
  • SONN 31.5K
  • Earning Date
  • EMR 05-07-2025
  • SONN 05-16-2025
  • Dividend Yield
  • EMR 1.88%
  • SONN N/A
  • EPS Growth
  • EMR N/A
  • SONN N/A
  • EPS
  • EMR 4.20
  • SONN N/A
  • Revenue
  • EMR $17,607,000,000.00
  • SONN $1,000,000.00
  • Revenue This Year
  • EMR $3.42
  • SONN $5,376.22
  • Revenue Next Year
  • EMR $4.95
  • SONN N/A
  • P/E Ratio
  • EMR $32.50
  • SONN N/A
  • Revenue Growth
  • EMR 6.52
  • SONN 674.14
  • 52 Week Low
  • EMR $90.06
  • SONN $1.10
  • 52 Week High
  • EMR $134.85
  • SONN $16.00
  • Technical
  • Relative Strength Index (RSI)
  • EMR 62.64
  • SONN 44.48
  • Support Level
  • EMR $106.53
  • SONN $1.30
  • Resistance Level
  • EMR $115.00
  • SONN $1.37
  • Average True Range (ATR)
  • EMR 3.10
  • SONN 0.09
  • MACD
  • EMR 1.48
  • SONN -0.01
  • Stochastic Oscillator
  • EMR 85.91
  • SONN 13.79

About SONN Sonnet BioTherapeutics Holdings Inc.

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Share on Social Networks: